Calliditas Therapeutics IPO Presentation Deck

calliditas THERAPEUTICS A clinical-stage biopharma company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet needs Lead product candidate, Nefecon, being developed for the treatment of IgA Nephropathy (IgAN), a serious progressive autoimmune disease of the kidney with no currently approved treatments Part A of Pivotal Phase 3 trial in IgAN fully recruited with topline readout expected in 4Q 2020; anticipated NDA and MAA filings in 1H 2021 for accelerated approval in U.S. and conditional approval in E.U. Headquartered in Stockholm, Sweden; listed on OMX NASDAQ in Sweden - Midcap segment (ticker: CALTX) Market cap as of May 27, 2020: ~US$392 million; Cash balance as of March 31, 2020: US$77 million, providing financing into 2H 2021 through planned regulatory filings for marketing approval in the U.S. and E.U. Key institutional shareholders include: Industrifonden (swe), Investinor (nor), BVF Capital, Vivo Capital, Sofinnova Partners calliditas June 2020 5

View entire presentation